Table 1.
Baseline Characteristics
| Control (n=72) | HFpEF (n=134) | p value | |
|---|---|---|---|
| Anthropometrics | |||
| Age, years | 54±16 | 67±11 | <0.0001 |
| Female, n (%) | 58 | 60 | 0.8 |
| Body mass index, kg/m2 | 28.4±5.8 | 32.7±6.8 | <0.0001 |
|
| |||
| Comorbidities | |||
| Diabetes, % | 10 | 25 | 0.007 |
| Angiographic CAD, % (n=46/88) | 28 | 31 | 0.8 |
| Hypertension, % | 84 | 96 | 0.007 |
| Atrial fibrillation, % | 6 | 20 | 0.004 |
|
| |||
| Laboratories | |||
| Hemoglobin, g/dl | 12.7±1.5 | 12.2±1.4 | 0.005 |
| eGFR, ml/min | 92±24 | 80±25 | 0.0009 |
| NT proBNP, pg/ml | 78 [29, 187] | 435 [107, 1134] | <0.0001 |
|
| |||
| Medications | |||
| ACE inhibitor/ARB, % | 31 | 50 | 0.007 |
| Beta blocker, % | 35 | 65 | <0.0001 |
| Diuretic, % | 32 | 55 | 0.002 |
|
| |||
| Echocardiography | |||
| LVEDD, mm | 48±5 | 49±6 | 0.5 |
| EF, % | 63±5 | 62±6 | 0.4 |
| LAVI, ml/m2 | 30±12 | 40±15 | <0.0001 |
| E/e’ ratio | 10±4 | 13±6 | <0.0001 |
| RVSP, mmHg | 29±5 | 37±11 | <0.0001 |
Values are expressed as mean ± standard deviation or number (percentage), CAD- Coronary Artery Disease, ACE-Angiotensin Converting Enzyme, ARB-Angiotensin Receptor Blocker, eGFR- estimated glomerular filtration rate, NT pro BNP- N terminal pro Brain Natriuretic Peptide, LVEDD- Left ventricular end diastolic dimension, LAVI- Left Atrial Volume Index, E- Early diastolic mitral inflow velocity, e’-early diastolic septal tissue Doppler velocity, EF- Ejection Fraction, RVSP-Right Ventricular Systolic Pressure